HDBuzz reported live updates on Bluesky from the 2025 HD Therapeutics Conference. Read on for coverage of Day 3. #CHDI2025 ...

New research suggests that cognitive engagement - keeping your brain busy with activities like reading, puzzles, or learning ...

We’re back for day 2 of the CHDI Huntington’s Disease Therapeutics Conference! We’re kicking things off with some exciting talks on genetic modifiers and learning how we can advance them toward ...

Up first is Amy-Lee Breadlau from PTC Therapeutics with an update on votoplam, formerly PTC-518. Votoplam is a HTT-lowering drug that’s taken as a pill. The idea is that by lowering the ...

A new study led by researchers from the University of California Irvine gives us new clues as to how genetic message molecules are edited differently in the context of Huntington’s disease (HD). Let’s ...

In plain language. Written by scientists. For the global HD community.